全文获取类型
收费全文 | 1677篇 |
免费 | 212篇 |
国内免费 | 60篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 42篇 |
妇产科学 | 7篇 |
基础医学 | 106篇 |
口腔科学 | 16篇 |
临床医学 | 118篇 |
内科学 | 575篇 |
皮肤病学 | 16篇 |
神经病学 | 11篇 |
特种医学 | 89篇 |
外科学 | 32篇 |
综合类 | 20篇 |
预防医学 | 38篇 |
眼科学 | 5篇 |
药学 | 76篇 |
中国医学 | 2篇 |
肿瘤学 | 795篇 |
出版年
2023年 | 14篇 |
2022年 | 9篇 |
2021年 | 28篇 |
2020年 | 22篇 |
2019年 | 34篇 |
2018年 | 46篇 |
2017年 | 32篇 |
2016年 | 36篇 |
2015年 | 53篇 |
2014年 | 52篇 |
2013年 | 90篇 |
2012年 | 76篇 |
2011年 | 94篇 |
2010年 | 65篇 |
2009年 | 70篇 |
2008年 | 81篇 |
2007年 | 134篇 |
2006年 | 90篇 |
2005年 | 57篇 |
2004年 | 63篇 |
2003年 | 94篇 |
2002年 | 65篇 |
2001年 | 58篇 |
2000年 | 43篇 |
1999年 | 63篇 |
1998年 | 38篇 |
1997年 | 40篇 |
1996年 | 29篇 |
1995年 | 27篇 |
1994年 | 36篇 |
1993年 | 25篇 |
1992年 | 23篇 |
1991年 | 29篇 |
1990年 | 22篇 |
1989年 | 28篇 |
1988年 | 33篇 |
1987年 | 32篇 |
1986年 | 16篇 |
1985年 | 15篇 |
1984年 | 10篇 |
1983年 | 10篇 |
1982年 | 14篇 |
1981年 | 12篇 |
1980年 | 8篇 |
1978年 | 7篇 |
1977年 | 7篇 |
1976年 | 10篇 |
1975年 | 4篇 |
1966年 | 1篇 |
1957年 | 1篇 |
排序方式: 共有1949条查询结果,搜索用时 109 毫秒
1.
Hagop Kantarjian Tapan Kadia Courtney DiNardo Naval Daver Gautam Borthakur Elias Jabbour Guillermo Garcia-Manero Marina Konopleva Farhad Ravandi 《Blood cancer journal》2021,11(2)
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhibitors, IDH inhibitors, and others. The management of AML is complicated, highlighting the need for expertise in order to deliver optimal therapy and achieve optimal outcomes. The multiple subentities in AML require very different therapies. In this review, we summarize the important pathophysiologies driving AML, review current therapies in standard practice, and address present and future research directions.Subject terms: Prognosis, Health services 相似文献
2.
Balloon dacryocystoplasty: indications and contraindications 总被引:3,自引:0,他引:3
3.
R S Walters H M Kantarjian M J Keating M Talpaz C C Childs K B McCredie E J Freireich 《Cancer》1987,60(8):1708-1712
Thirty patients with Philadelphia chromosome-positive lymphoid (20 patients) or undifferentiated (ten patients) chronic myelogenous leukemia in blast crisis were treated with 0.4 mg of vincristine by continuous intravenous infusion (CIV) daily for 4 days; (doxorubicin) 12 mg/m2 of Adriamycin (Adria Laboratories, Columbus, OH) by continuous intravenous infusion daily for 4 days; and 40 mg of decadron daily on days 1 through 4, 9 through 12, and 17 through 20 (VAD). Course 2 was given starting on day 24 with the addition of cyclophosphamide 1 g/22. Overall nine patients achieved complete remission (30%) and three attained a partial remission (10%), for an overall response rate of 40%. Four patients expired during induction whereas 14 had resistant disease. Response rate was significantly higher for patients with lymphoid compared to undifferentiated morphology (55% versus 10%; P = 0.05). In lymphoid blast crisis, Calla-positive disease was associated with a higher response rate compared to Calla-negative disease (75% versus 25%; P = 0.08). Eleven patients developed infections, and seven had fever without documented infections. The median overall survival was 29 weeks. Median survival was 43 weeks for patients achieving complete remission and 20 weeks for those with resistant disease. Remission duration was 39 weeks. After primary and salvage therapy, nine patients are alive, six of them in continuous remission for 19+ to 112+ weeks. The authors conclude that VAD chemotherapy is an effective regimen with acceptable toxicity in patients with lymphoid blast crisis especially those with Calla-positive disease. Alternate induction regimens for undifferentiated disease and for maintenance therapy are currently being investigated. 相似文献
4.
O'Brien SG Guilhot F Larson RA Gathmann I Baccarani M Cervantes F Cornelissen JJ Fischer T Hochhaus A Hughes T Lechner K Nielsen JL Rousselot P Reiffers J Saglio G Shepherd J Simonsson B Gratwohl A Goldman JM Kantarjian H Taylor K Verhoef G Bolton AE Capdeville R Druker BJ;IRIS Investigators 《The New England journal of medicine》2003,348(11):994-1004
5.
Duncan WC; Illingworth PJ; Young FM; Fraser HM 《Human reproduction (Oxford, England)》1998,13(9):2532-2540
The molecular mechanisms involved in luteolysis are still unclear in the
primate. This study aimed to investigate the effect of induced luteolysis
on the ovarian luteinizing hormone (LH) receptor and the steroidogenic
enzyme, 3beta-hydroxysteroid dehydrogenase (3beta-HSD) in the marmoset
monkey. Luteolysis was induced in the mid-luteal phase either directly by
systemic prostaglandin F2alpha (PGF2alpha), or indirectly by LH withdrawal
using systemic gonadotrophin releasing hormone antagonist (GnRHant)
treatment. The LH receptor was studied by isotopic mRNA in-situ
hybridization and in-situ ligand binding and 3beta-HSD expression was
studied using isotopic mRNA in-situ hybridization and immunohistochemistry.
Induced luteolysis was associated with a reduction in the expression of LH
receptor (P < 0.0001) and 3beta-HSD mRNA, closely followed by a
reduction in the LH receptor (P < 0.05) and 3beta-HSD protein
concentrations within 24 h. There were no differences in the findings
whether luteolysis was induced with PGF2alpha or GnRHant. This study shows
that disparate mechanisms to induce luteolysis in the primate result in an
identical rapid loss of the LH receptor and 3beta-HSD. In conclusion,
induced luteolysis leads to rapid loss of the steroidogenic pathway in
luteal cells.
相似文献
6.
HM Clink 《Journal of clinical pathology》1980,33(8):799-800
7.
8.
Semen parameters and testicular pathology in men with testicular cancer and contralateral carcinoma in situ or bilateral testicular malignancies 总被引:2,自引:2,他引:2
Kliesch S; Bergmann M; Hertle L; Nieschlag E; Behre HM 《Human reproduction (Oxford, England)》1997,12(12):2830-2835
We evaluated 14 patients with bilateral testicular tumour, one-sided tumour
and contralateral carcinoma in situ (CIS) of the testis or testis tumour in
single testis with respect to their fertility. We analysed semen
parameters, serum hormones [follicle-stimulating hormone (FSH), luteinizing
hormone (LH) and testosterone], testicular sonography, testicular volumes
and testicular histology prior to further anti-cancer treatment. Ten out of
14 patients showed normal or reduced sperm concentrations, while 4/14
patients were azoospermic. Serum FSH levels showed a significant negative
correlation with sperm concentrations in patients with testicular
malignancies (r = -0.64, P = 0.025). Testicular volumes revealed a
significant positive correlation with semen parameters in patients with
testes that were affected by CIS (r = 0.733, P = 0.038). We conclude that
even bilateral testicular cancer and/or CIS do not preclude fertility and,
therefore, patients should be offered andrological investigation and
therapy, including possibly surveillance strategy or the chance for
cryopreservation of the semen prior to further treatment in order to
preserve their chances for paternity.
相似文献
9.
10.
Survey of CAG/CTG repeats in human cDNAs representing new genes: candidates for inherited neurological disorders 总被引:3,自引:2,他引:3
Neri C; Albanese V; Lebre AS; Holbert S; Saada C; Bougueleret L; Meier-Ewert S; Le Gall I; Millasseau P; Bui H; Giudicelli C; Massart C; Guillou S; Gervy P; Poullier E; Rigault P; Weissenbach J; Lennon G; Chumakov I; Dausset J; Lehrach H; Cohen D; Cann HM 《Human molecular genetics》1996,5(7):1001-1009